Compare Adaptive Biotechnologies Corp (ADPT) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Cognizant Technology Solutions Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Cognizant Technology Solutions Corp trades at $57.8 (market cap $26.40B). The key difference: Cognizant Technology Solutions Corp is far larger — about 6.5× Adaptive Biotechnologies Corp's market cap, and Cognizant Technology Solutions Corp pays a 2.25% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CTSH | |
|---|---|---|
Market Cap | $4.04B | $26.40B |
Sector | Health | Technology |
52-Week High | $25.45 | $86.70 |
52-Week Low | $12.30 | $38.73 |
Enterprise Value | $4.10B | $27.44B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTSH trades at $58.31, up 1.11% today, near its consensus price target of $59.92. The stock shows bullish technical signals with moving averages supporting an uptrend, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed estimates, but revenue beat expectations, and the company maintains strong profitability with a net margin of 10.26%. AI initiatives and financial services growth are key drivers, as highlighted in recent earnings calls (Seeking Alpha, 2026-07-29).
Outlook: CTSH offers value with a P/E of 12.58 and stable cash flows, but faces risks from client spending caution and competitive pressures. Upside potential exists if AI investments yield growth, though macroeconomic headwinds could limit near-term gains. Analysts are mixed, with 43% recommending buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
